VCRE (Vicore Pharma Holding AB) 1-Year Sharpe Ratio: N/A (As of Jul. 07, 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.60
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-07), Vicore Pharma Holding AB's 1-Year Sharpe Ratio is Not available.


Vicore Pharma Holding AB  (NAS:VCRE) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Vicore Pharma Holding AB 1-Year Sharpe Ratio Related Terms


VCRE vs : 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 1-Year Sharpe Ratio falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60
Price